China Waives Import Tariffs for Active Ingredients of Anti-cancer and Rare Disease Drugs in 2024

by Grace Wang Jan 01, 2024

According to the 2024 Tariff Adjustment Plan recently published by the Customs Tariff Commission of the State Council, China waives import tariffs for 62 active pharmaceutical ingredients (API) of anti-cancer drugs and 5 APIs of rare disease drugs, starting from January 1, 2024.

The plan covers 1,010 commodities, with interim import tax rates being set lower than most-favored-nation tariffs for the year 2024. 

Notably, certain medical products will be exempted from import taxes. Apart from APIs for the anti-cancer and rare disease drugs listed below, medical products such as nirmatrelvir for COVID-19, insulins for diabetes, vaccines, gene therapies, and more will also enjoy interim zero tariffs. 

Table: APIs of anti-cancer and rare disease drugs exempted from China’s import tariffs in 2024

No.

Tax code

Commodity

2024 MFN tariff %

2024 interim tariff %

APIs of drugs for cancer

1

28439000

Ÿ   Oxaliplatin;

Ÿ   Carboplatin;

Ÿ   Nedaplatin;

Ÿ   Cisplatin

5.5

0

2

28459000

Ÿ   Donafenib tosilate

5

0

3

29053990

Ÿ   Busulfan

5.5

0

4

29225090

Ÿ   Mitoxantrone hydrochloride

6.5

0

5

29242990

Ÿ   Flutamide

6.5

0

6

29309090

Ÿ   Bicalutamide

6.5

0

7

29329990

Ÿ   Docetaxel;

Ÿ   Paclitaxel

6.5

0

8

29329990

Ÿ   Icariin

6.5

0

9

29331990

Ÿ   Savolitinib

6.5

0

10

29333990

Ÿ   Gimestat;

Ÿ   Apatinib mesylate;

Ÿ   Chidamide

Ÿ   Niraparib tosilate

6.5

0

11

29334900

Ÿ   Pyrotinib maleate

6.5

0

12

29335990

Ÿ   Imatinib mesylate;

Ÿ   Azathioprine;

Ÿ   Pemetrexed disodium;

Ÿ   Calcium levofolinate;

Ÿ   Flumatinib mesylate;

Ÿ   Almonertinib mesylate;

Ÿ   Zanubrutinib;

Ÿ   Olverembatinib

6.5

0

13

29336990

Ÿ   Oteracil potassium

6.5

0

14

29337900

Ÿ   Lenalidomide

9

0

15

29339900

Ÿ   Anastrozole;

Ÿ   Letrozole;

Ÿ   Bortezomib;

Ÿ   Temozolomide;

Ÿ   Pamiparib

6.5

0

16

29341090

Ÿ   Dasatinib

6.5

0

17

29349990

Ÿ   Decitabine;

Ÿ   Floxuridine;

Ÿ   Cyclophosphamide;

Ÿ   Gefitinib;

Ÿ   Capecitabine;

Ÿ   Raltitrexed;

Ÿ   Fludarabine phosphate;

Ÿ   Tegafur;

Ÿ   Cytarabine;

Ÿ   Cytarabine hydrochloride;

Ÿ   Icotinib hydrocholride;

Ÿ   Gemcitabine hydrochloride;

Ÿ   Ifosfamide;

Ÿ   Fruquintinib

6.5

0

18

29371900

Ÿ   Triptorelin acetate

4

0

19

29372319

Ÿ   Formestane

4

0

20

29372900

Ÿ   Exemestane

4

0

21

29397990

Ÿ   Vinorelbine tartrate;

Ÿ   Vincristine sulfate;

Ÿ   Topotecan hydrochloride

Ÿ   Irinotecan hydrochloride

4

0

22

29419090

Ÿ   Pirarubicin;

Ÿ   Mitomycin;

Ÿ   Epirubicin hydrochloride;

Ÿ   Doxorubicin hydrochloride;

Ÿ   Bleomycin A5 ydrochloride;

Ÿ   Daunorubicin hydrochloride;

Ÿ   Idarubicin hydrochloride

6

0

APIs of drugs for rare diseases

1

29309090

Ÿ   Penicillamine

6.5

0

2

29337900

Ÿ   Pirfenidone

9

0

3

29342000

Ÿ   Riluzole

6.5

0

4

29359000

Ÿ   Bosentan

6.5

0

5

29375000

Ÿ   Treprostinil

4

0

Contact BaiPharm if you'd like to know more about drug regulations and policies in China.

Subscribe to ChemLinked BaiPharm Newsletter.png

Grace Wang
ChemLinked Regulatory Analyst & Editor
+ FOLLOW
Copyright: unless otherwise stated all contents of this website are ©2024 - REACH24H Consulting Group - All Rights Reserved - For permission to use any content on this site, please contact cleditor@chemlinked.com
You May Also Like
Most Popular